Patel Sanj K

Average Profitability
<0.0001%
Insider Buys Quantity
1
Insider Buys Sum
$999,982.98
Insider Sells Quantity
11
Insider Sells Sum
$21.68M

Insider Activity of Patel Sanj K

According to the SEC Form 4 filings, Patel Sanj K, being in a position of

  1. CHAIRMAN & CEO at Kiniksa Pharmaceuticals, Ltd.,
    оver the last 12 months, has bought 0 shares, and sold 309021 share for $7.31M,
    over all time since 2018-02-09, has bought 127844 shares for $999,983, and sold 990713 shares for $21.68M.

The largest purchase of all time was on 2018-02-09 and amounted to 127844 shares of Kiniksa Pharmaceuticals, Ltd. for $999,983.

The largest sale of all time was on 2020-10-12 and amounted to 500060 shares of Kiniksa Pharmaceuticals, Ltd. for $10.51M.

Biography of Patel Sanj K

No biography is available at this moment.

2024-11-06SaleKiniksa Pharmaceuticals, Ltd.
KNSA
CHAIRMAN & CEO
89,561
0.1239%
$23.00$2.06M-7.49%
2024-07-23SaleKiniksa Pharmaceuticals, Ltd.
KNSA
CHAIRMAN & CEO
136,124
0.1877%
$25.65$3.49M+1%
2024-03-07SaleKiniksa Pharmaceuticals, Ltd.
KNSA
CHAIRMAN & CEO
65,012
0.0919%
$21.02$1.37M-0.8%
2024-03-06SaleKiniksa Pharmaceuticals, Ltd.
KNSA
CHAIRMAN & CEO
5,582
0.008%
$21.00$117,222+0.62%
2024-03-04SaleKiniksa Pharmaceuticals, Ltd.
KNSA
CHAIRMAN & CEO
12,742
0.0194%
$21.49$273,834+4.19%
2021-02-10SaleKiniksa Pharmaceuticals, Ltd.
KNSA
Chairman & CEO
5,474
0.0085%
$23.06$126,253-38.71%
2021-02-09SaleKiniksa Pharmaceuticals, Ltd.
KNSA
Chairman & CEO
87,940
0.1324%
$23.06$2.03M-40.33%
2021-02-08SaleKiniksa Pharmaceuticals, Ltd.
KNSA
Chairman & CEO
18,904
0.0209%
$17.42$329,369-41.64%
2020-10-12SaleKiniksa Pharmaceuticals, Ltd.
KNSA
Chairman & CEO
500,060
0.8036%
$21.02$10.51M-25.98%
2020-10-09SaleKiniksa Pharmaceuticals, Ltd.
KNSA
Chairman & CEO
3,084
0.0037%
$15.51$47,838-25.06%
2020-03-06SaleKiniksa Pharmaceuticals, Ltd.
KNSA
Chairman & CEO
66,230
0.1212%
$20.00$1.32M-3.85%
2018-02-09PurchaseKiniksa Pharmaceuticals, Ltd.
KNSA
Chairman & CEO
127,844
$7.82$999,983
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.